---
title: "KELUN PHARMA: The net profit for the third quarter was 200 million yuan, a year-on-year decrease of 70.18%"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/263503708.md"
description: "KELUN PHARMA announced that its revenue for the third quarter was 4.193 billion yuan, a year-on-year decrease of 15.48%; net profit was 200 million yuan, a year-on-year decrease of 70.18%. Revenue for the first three quarters was 13.277 billion yuan, a year-on-year decrease of 20.92%; net profit was 1.201 billion yuan, a year-on-year decrease of 51.41%"
datetime: "2025-10-30T11:24:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263503708.md)
  - [en](https://longbridge.com/en/news/263503708.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263503708.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/263503708.md) | [繁體中文](https://longbridge.com/zh-HK/news/263503708.md)


# KELUN PHARMA: The net profit for the third quarter was 200 million yuan, a year-on-year decrease of 70.18%

KELUN PHARMA announced that its revenue for the third quarter was 4.193 billion yuan, a year-on-year decrease of 15.48%; net profit was 200 million yuan, a year-on-year decrease of 70.18%. Revenue for the first three quarters was 13.277 billion yuan, a year-on-year decrease of 20.92%; net profit was 1.201 billion yuan, a year-on-year decrease of 51.41%

### 相关股票

- [KELUN PHARMA (002422.CN)](https://longbridge.com/zh-CN/quote/002422.CN.md)

## 相关资讯与研究

- [Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results](https://longbridge.com/zh-CN/news/278713493.md)
- [06:47 ETKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis](https://longbridge.com/zh-CN/news/278376120.md)
- [Paralympics-Broken kit, no problem: the Paralympics rapid‑repair lifeline](https://longbridge.com/zh-CN/news/279096386.md)
- [Volkswagen reclaims top spot in China car sales, BYD falls to fourth as EV subsidies fade](https://longbridge.com/zh-CN/news/279028881.md)
- [Clover Biopharmaceuticals Sets Board Meeting to Approve 2025 Results and Consider Dividend](https://longbridge.com/zh-CN/news/279032574.md)